Table 3 Post hoc sensitivity analyses
Sensitivity analyses | Lack of blinding on participants | Lack of blinding on health care providers | Lack of blinding on outcome assessors |
|---|---|---|---|
Funding sources | |||
 Industry funded | 0.65 (95% CI: 0.48 to 0.88) | 0.65 (95% CI: 0.49 to 0.88) | 1.01 (95% CI: 0.94 to 1.08) |
Year of publication | |||
 2000 ~ 2010 | 0.73 (95% CI: 0.57 to 0.93) | 0.73 (95% CI: 0.57 to 0.93) | 0.90 (95% CI: 0.68 to 1.18) |
 2011 ~ 2020 | 0.38 (95% CI: 0.22 to 0.67) | 0.33 (95% CI: 0.23 to 0.48) | 1.03 (95% CI: 0.96 to 1.10) |
Region | |||
 Europe and North America | 0.95 (95% CI: 0.20 to 4.53) | 0.75 (95% CI: 0.19 to 2.90) | 0.90 (95% CI: 0.72 to 1.13) |
 Multiple countries | 0.65 (95% CI: 0.47 to 0.90) | 0.66 (95% CI: 0.48 to 0.90) | 0.95 (95% CI: 0.88 to 1.02) |
 Others | 0.22 (95% CI: 0.15 to 0.31) | 0.22 (95% CI: 0.15 to 0.30) | 0.84 (95% CI: 0.49 to 1.44) |
Sample size | |||
 Less than 500 | 0.56 (95% CI: 0.36 to 0.86) | 0.50 (95% CI: 0.34 to 0.73) | 0.91 (95% CI: 0.80 to 1.03) |
 500 or more | 0.68 (95% CI: 0.51 to 0.91) | 0.68 (95% CI: 0.51 to 0.91) | 1.05 (95% CI: 0.95 to 1.16) |